<DOC>
	<DOC>NCT01233258</DOC>
	<brief_summary>The objective of the trial is to demonstrate that 2-3 times per week prophylaxis therapy with BAY81-8973 is superior to on-demand therapy with BAY81-8973 in patients with severe Hemophilia A. The hypothesis is that prophylaxis will result in fewer bleeds than on-demand treatment.</brief_summary>
	<brief_title>A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male, aged 12 to 65 years Severe hemophilia A History of more than 150 exposure days (ED) with clotting factor concentrates Currently receiving episodic treatment with FVIII; no regular prophylaxis for more than 6 consecutive months in the past 5 years No current Factor VIII inhibitor or history of inhibitor Willing to use electronic patient diary Presence of another bleeding disease that is different from hemophilia A Thrombocytopenia Abnormal renal function Presence of active liver disease Known hypersensitivity to FVIII</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Haemophilia treatment</keyword>
	<keyword>rFVIII</keyword>
</DOC>